| Ytd | 80.71% | |
| 1y | 189.02% |
| Open | 74.29 | Prev Close | 74.71 | Low | 73.55 | High | 75.66 | Mkt Cap | 6.62B |
| Vol | 584.14K | Avg Vol | 1.03M | EPS | -2.69 | P/E | -27.89 | Forward P/E | -25.84 |
| Beta | 0.23 | Short Ratio | 12.31 | Inst. Own | 114.41% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-07 | 50-d Avg | 68.30 | 200-d Avg | 58.22 | 1yr Est | 91.08 |
CGON News
CG Oncology is advancing cretositimogene grenadenorepvec (cret) for NMIBC, showing strong efficacy a
California State Teachers Retirement System increased its stake in CG Oncology, Inc. (NASDAQ: CGON)
CG Oncology, Inc. (CGON) came out with a quarterly loss of $0.9 per share versus the Zacks Consensus
DALLAS, Texas, Aug. 06, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today reported fin
NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is i
Data reinforce durable responses, bladder preservation, low rate of disease progression, and favorab
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) (ANI or the Company) today announced that Judge Sheldon K. R
CGON climbs as cretostimogene nears a planned 2026 BLA filing, posts encouraging phase II data. It m
CG Oncology NASDAQ: CGON Chief Executive Officer Arthur outlined the company's upcoming clinical and
CG Oncology, Inc. (CGON) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Tra
CG Oncology NASDAQ: CGON is focused on advancing cretostimogene, an oncolytic immunotherapy for non-
DALLAS, May 28, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthu
CG Oncology NASDAQ: CGON executives used an RBC Capital Markets fireside chat to outline recent clin
Patrick Hensley, MD and Daniel Joyce, MD, MS each received a grant up to $50,000.00 to support the d
- High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the IT
CG Oncology NASDAQ: CGON executives said the company remains on track to complete a rolling biologic
CG Oncology, Inc. (CGON) Presents at Bank of America Global Healthcare Conference 2026 Transcript
-First results from CORE-008 Cohort CX Phase 2 Trial evaluating intravesical combination therapy in
CG Oncology (NASDAQ:CGON) reported mixed results for the first quarter on Friday.
CG Oncology, Inc. (CGON) came out with a quarterly loss of $0.71 per share versus the Zacks Consensu
DALLAS, May 08, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today reported financial r
